How to Treat Opiate Withdrawal in Neonates
Primary Purpose
Neonatal Abstinence Syndrome
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Phenobarbital
Chlorpromazine
Morphine
Sponsored by
About this trial
This is an interventional treatment trial for Neonatal Abstinence Syndrome focused on measuring opiate dependence, withdrawal, newborn
Eligibility Criteria
Inclusion Criteria:
- Neonates of mothers who consumed opiates during pregnancy
- Born after 34 completed weeks of pregnancy
- Parents' informed consent
Exclusion Criteria:
- Preterm birth before 34 0/7 gestational weeks
- Severe malformation
- Illness requiring respiratory assistance or catecholamines
- Negative meconium drug test
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
Phenobarbital
Chlorpromazine
Morphine
Arm Description
Phenobarbitone loading dose 10 mg/kg body weight maintenance dose 0.83 mg/kg body weight every 4 hours
Chlorpromazine loading dose 0.5 mg/kg body weight maintenance dose 0.25 mg/kg every 4 hours
Morphine (tinctura opii) 0.25 mg/kg body weight every 4 hours
Outcomes
Primary Outcome Measures
Duration of treatment
Treatment is reduced stepwise until withdrawal symptoms have gone
Secondary Outcome Measures
Incidence of convulsions
Weight gain
Treatment failures (need for adding second medication)
Need for additional drug if investigational drug does not control withdrawal symptoms
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02810782
Brief Title
How to Treat Opiate Withdrawal in Neonates
Official Title
Pharmacological Treatment of Narcotic Neonatal Withdrawal
Study Type
Interventional
2. Study Status
Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
June 2001 (undefined)
Primary Completion Date
December 2007 (Actual)
Study Completion Date
December 2007 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Zurich
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Three different drugs are used in a randomised, double blind, clinical multi-centre trial with three arms. Major objective is to investigate the duration of drug treatment based on the Finnegan score. Secondary objectives are to document weight gain, the need for adding a second drug when the first drug is not effective enough and possible side effects such as convulsions.
Detailed Description
Background: Neonatal narcotic abstinence syndrome is an important medical, social and financial problem. Several drugs are used to treat the withdrawal symptoms in neonates that have been exposed to opiates in utero, but there is no consensus which one is best.
Goal: Three different drugs are used in a randomised, double blind, clinical multi-centre trial with three arms. Major objective is to investigate the duration of drug treatment based on the Finnegan score. Secondary objectives are to document weight gain, the need for adding a second drug when the first drug is not effective enough and possible side effects such as convulsions.
Methods: Neonates born after 34 completed weeks of gestation with meconium proven antenatal opiate exposure and parental informed consent are included. Infants with severe malformation are excluded. Each infant is assessed every eight hour by a modified Finnegan score. When 9 points are exceeded drug treatment is started and dose increased stepwise according to the score. The masqued solution applied orally contains morphine, phenobarbital or chlorpromazine. When the maximum dose does not reduce the score, a second randomisation and one of the two remaining drugs is added, again in a blinded way.
A total of 120 infants, 40 in each group will be included in the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neonatal Abstinence Syndrome
Keywords
opiate dependence, withdrawal, newborn
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Phenobarbital
Arm Type
Experimental
Arm Description
Phenobarbitone loading dose 10 mg/kg body weight maintenance dose 0.83 mg/kg body weight every 4 hours
Arm Title
Chlorpromazine
Arm Type
Active Comparator
Arm Description
Chlorpromazine loading dose 0.5 mg/kg body weight maintenance dose 0.25 mg/kg every 4 hours
Arm Title
Morphine
Arm Type
Active Comparator
Arm Description
Morphine (tinctura opii) 0.25 mg/kg body weight every 4 hours
Intervention Type
Drug
Intervention Name(s)
Phenobarbital
Other Intervention Name(s)
Phenobarbitone
Intervention Description
Phenobarbital per os
Intervention Type
Drug
Intervention Name(s)
Chlorpromazine
Other Intervention Name(s)
Largactil
Intervention Description
Chlorpromazine per os
Intervention Type
Drug
Intervention Name(s)
Morphine
Other Intervention Name(s)
tinctura opii
Intervention Description
Morphine per os
Primary Outcome Measure Information:
Title
Duration of treatment
Description
Treatment is reduced stepwise until withdrawal symptoms have gone
Time Frame
0 to 42 days
Secondary Outcome Measure Information:
Title
Incidence of convulsions
Time Frame
Whole time of hospitalisation (up to 10 weeks)
Title
Weight gain
Time Frame
through study completion, up to 10 weeks
Title
Treatment failures (need for adding second medication)
Description
Need for additional drug if investigational drug does not control withdrawal symptoms
Time Frame
through study completion, up to 10 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Hour
Maximum Age & Unit of Time
3 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Neonates of mothers who consumed opiates during pregnancy
Born after 34 completed weeks of pregnancy
Parents' informed consent
Exclusion Criteria:
Preterm birth before 34 0/7 gestational weeks
Severe malformation
Illness requiring respiratory assistance or catecholamines
Negative meconium drug test
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hans U Bucher, Prof
Organizational Affiliation
University of Zurich
Official's Role
Study Chair
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
31691849
Citation
Zimmermann U, Rudin C, Duo A, Held L, Bucher HU; Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. Eur J Pediatr. 2020 Jan;179(1):141-149. doi: 10.1007/s00431-019-03486-6. Epub 2019 Nov 6.
Results Reference
result
Learn more about this trial
How to Treat Opiate Withdrawal in Neonates
We'll reach out to this number within 24 hrs